In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), ...

PTC Therapeutics (PTCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Lebowitz ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...

Shares of PTC Therapeutics Inc. climbed nearly 1% pre-market Tuesday, poised to extend their rally to levels last seen in April 2023. The stock’s momentum follows the company’s $1 billion ...

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...

Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential oral therapy for Huntington's disease (HD). The PTC518 Huntington's ...

2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with ...

WARREN, N.J., Nov. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher ...

WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing ...